Table 4.
Receiver Operating Curve Analysis: Optimal Time for mAb Administration After Symptom Onset
| Outcome | AUC (95% CI) | Sensitivity | Specificity | |
|---|---|---|---|---|
| Day 29 COVID-19 hospitalization and/or ED visit | 0.66 (.54–.76) | 67% | 56% | |
| Day 29 COVID-19 hospitalization | 0.76 (.64–.85) | 74% | 75% | |
| Day 29 COVID-19 ED visit | 0.53 (.31–.69) | 50% | 53% | |
| Impact of mAb Earlier vs. Later than 6 Days from Symptom Onset | ||||
| mAb Administered ≤ 6 d of Symptoms (n = 143) | mAb Administered > 6 d of Symptoms (n = 57) | NNT | P value | |
| Day 29 COVID-19 hospitalization and/or ED visit, No. (%) | 11 (7.7) | 16 (28.1) | 5 | |
| Unadjusted OR (95% CI) | 0.21 (.09–.5) | <.001 | ||
| Adjusted OR (95% CI) | 0.22 (.09–.53) | <.001 |
Bold P Values denote statistical significance (P < .05).
Abbreviations: AUC, area under the curve; CI, confidence interval; COVID-19, coronavirus disease 2019; ED, emergency department; mAb, monoclonal antibody; NNT, number needed to treat; OR, odds ratio.